Monika Talarowska1, Janusz Szemraj2, Piotr Gałecki3. 1. Department of Adult Psychiatry, Medical University of Lodz, Lodz, Poland. Electronic address: talarowkamonika@wp.pl. 2. Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland. 3. Department of Adult Psychiatry, Medical University of Lodz, Lodz, Poland.
Abstract
PURPOSE: Most researchers agree that there are multiple factors influencing the development of recurrent depressive disorder (rDD). Previous studies have found that myeloperoxidase (MPO) may be a key inflammatory enzyme involved in this disorder. The purpose of this study was to determine the mRNA and protein levels of MPO in patients with rDD and to define the relationship between serum MPO levels and cognitive performance. MATERIAL/ METHODS: The study comprised 236 subjects: patients with rDD (n=131) and healthy subjects (n=105, HS). Assessment of cognitive function was based on performance on the Trail Making Test, the Stroop Test, the Verbal Fluency Test (VFT) and the Auditory-Verbal Learning Test (AVLT). RESULTS: MPO gene expression at mRNA level and at protein level was significantly higher in the rDD group when compared to the HS (p<0.01). There were no significant correlations for each group separately, but in the entire group, statistically significant correlations occurred between both mRNA and protein levels and following test: TMT part A and part B (positive correlations), part RCNb and part NCWd of the Stroop Test (positive correlation), the Verbal Fluency Test (negative correlation) and the AVLT (negative correlation). CONCLUSIONS: Our study provides evidence that the MPO enzyme coding gene and MPO expression are important for the regulation of cognitive functioning.
PURPOSE: Most researchers agree that there are multiple factors influencing the development of recurrent depressive disorder (rDD). Previous studies have found that myeloperoxidase (MPO) may be a key inflammatory enzyme involved in this disorder. The purpose of this study was to determine the mRNA and protein levels of MPO in patients with rDD and to define the relationship between serum MPO levels and cognitive performance. MATERIAL/ METHODS: The study comprised 236 subjects: patients with rDD (n=131) and healthy subjects (n=105, HS). Assessment of cognitive function was based on performance on the Trail Making Test, the Stroop Test, the Verbal Fluency Test (VFT) and the Auditory-Verbal Learning Test (AVLT). RESULTS:MPO gene expression at mRNA level and at protein level was significantly higher in the rDD group when compared to the HS (p<0.01). There were no significant correlations for each group separately, but in the entire group, statistically significant correlations occurred between both mRNA and protein levels and following test: TMT part A and part B (positive correlations), part RCNb and part NCWd of the Stroop Test (positive correlation), the Verbal Fluency Test (negative correlation) and the AVLT (negative correlation). CONCLUSIONS: Our study provides evidence that the MPO enzyme coding gene and MPO expression are important for the regulation of cognitive functioning.
Authors: Andrea Cruz-Baquero; Luz María Cárdenas Jaramillo; Manuel Gutiérrez-Meza; Rosa Adriana Jarillo-Luna; Rafael Campos-Rodríguez; Víctor Rivera-Aguilar; Angel Miliar-García; Judith Pacheco-Yepez Journal: PLoS One Date: 2017-08-10 Impact factor: 3.240
Authors: Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes Journal: BMC Med Date: 2020-10-19 Impact factor: 8.775
Authors: Yuan Fang; Margaret F Doyle; Jiachen Chen; Michael L Alosco; Jesse Mez; Claudia L Satizabal; Wei Qiao Qiu; Joanne M Murabito; Kathryn L Lunetta Journal: PLoS One Date: 2022-09-09 Impact factor: 3.752
Authors: Monika E Talarowska; Małgorzata Kowalczyk; Michael Maes; Andre Carvalho; Kuan-Pin Su; Janusz Szemraj; Piotr Gałecki Journal: Arch Med Sci Date: 2019-02-25 Impact factor: 3.318